Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the effects of Symbicort SiT and treatment according to
NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20
histamine, and to validate the Bronchial Hyperresponsiveness Questionnaire (BHQ).
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate